www.diseases-diagnosis.com Homepage Diseases Symptoms Diseases Diagnosis Diseases Treatment Diseases Living Care Diseases Prevention Diseases Research
www
Search
March 26, 2016
Table of Contents

1 Introduction
International Agency for Research on Cancer

Wikipedia

 

The International Agency for Research on Cancer ( IARC , or CIRC in its French acronym) is an intergovernmental agency forming part of the World Health Organisation of the United Nations.

Its main offices are in Lyon, France. Its role is to conduct and coordinate research into the causes of cancer. It also conducts epidemiological studies into the occurrence of cancer worldwide. It maintains a series of monographs on the carcinogenic risks to humans posed by a variety of agents, mixtures and exposures.




The IARC categorizes agents, mixtures and exposures into five categories.

  • Group 2A : probably carcinogenic to humans.

  • Group 2B : possibly carcinogenic to humans.

  • Group 3 : not classifiable as to carcinogenicity in humans.

  • Group 4: probably not carcinogenic to humans. Only one substance ??? caprolactam ??? has both been assessed for carcinogenicity by the IARC and placed in this category.




Critics of the IARC have stated that it has become susceptible to industry influence and suffers from a lack of transparency. Lorenzo Tomatis, its director from 1982 to 1993, was "barred from entering the building" in 2003 after "accusing the IARC of softpedaling the risks of industrial chemicals" Around 2003 thirty public-health scientists signed a letter targeting conflicts of interest and the lack of transparency.

Tomatis focused on the IARC monographs which rate chemicals carcinogenicity, and cited several cases in his 2002 critique. In 1998 a panel voted 17-13 to rate 1,3-butadiene a carcinogen. A second vote which Tomatis called "highly irregular" occurred after "industry observers schmoozed with the panelists and one panelist left the meeting", and a 15-14 vote downgraded the chemical to a "possible carcinogen".

IARC's secrecy led a Lancet Oncology editorial to warn of the agency's eroding reputation. As of 2003 the IARC did not release details of disputed votes, did not release the financial disclosure forms required of panelists, or the names of the panelists until the panel is complete. Individuals being considered for the new director are released only to representatives from the 16 member countries. Kleihues and other agency officials defend the IARC, with Kleihues noting that procedures and names are listed on the finished monographs, and said names are not released to avoid political pressures. The IARC was considering new transparency disclosures such as a "narrative" explaining disputed votes.




  • European Organisation for Research and Treatment of Cancer (EORTC)

  • Air pollution

  • Cancer

  • Carcinogen

  • Genotoxic

  • Mutagen

  • Toxicology





  • IARC official site



This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "International Agency for Research on Cancer".


Last Modified:   2010-11-25


Search
All informatin on the site is © www.diseases-diagnosis.com 2002-2011. Last revised: January 2, 2011
Are you interested in our site or/and want to use our information? please read how to contact us and our copyrights.
To let us provide you with high quality information, you can help us by making a more or less donation: